Every material Form 8-K BioMarin Pharmaceutical filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BioMarin agreed to acquire Amicus Therapeutics for $14.50 per share in cash, a total equity value of approximately $4.8 billion, through a merger in which Amicus becomes a wholly owned subsidiary. The deal requires approval by Amicus stockholders and antitrust clearances, and is expected to close in the second quarter of 2026. BioMarin plans to fund it with cash on hand and approximately $3.7 billion of non-convertible debt, and the companies say it is expected to be accretive to non-GAAP diluted EPS in the first 12 months after close.
Price of $14.50 per Amicus share in cash, a 33% premium to Amicus' last close
Total equity value of approximately $4.8 billion; financing includes approximately $3.7 billion of non-convertible debt
Amicus pays BioMarin a $175 million termination fee in specified circumstances
Expected close in the second quarter of 2026; End Date of June 19, 2026, subject to automatic extensions
BioMarin announced that Rashmi Ramchandani will become Vice President and Chief Accounting Officer on January 19, 2026, taking over as principal accounting officer from CFO Brian Mueller, who remains CFO. The filing sets out her pay package, including a $460,000 base salary and a $400,000 sign-on bonus, which matters to shareholders as a routine finance leadership change with defined compensation.
Ramchandani's effective start date is January 19, 2026; she becomes principal accounting officer from Brian Mueller, who stays EVP and CFO.
Compensation includes a $460,000 base salary, a $400,000 sign-on bonus, and a 45% target bonus payout starting in 2026.
Equity awards include RSUs valued at $1,050,000 and $400,000, and stock options valued at $450,000.
Ramchandani previously held accounting roles at Gilead Sciences and was a controller at Strava, Inc.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BioMarin Pharmaceutical filing is on SEC EDGAR ↗. 8-K briefs of other companies →